Jane Street Group LLC Raises Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)

Jane Street Group LLC increased its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 330.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,979 shares of the company's stock after buying an additional 30,681 shares during the period. Jane Street Group LLC owned about 0.21% of USANA Health Sciences worth $1,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in USNA. Dimensional Fund Advisors LP lifted its holdings in USANA Health Sciences by 7.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after purchasing an additional 55,059 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in USANA Health Sciences by 8.8% in the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock worth $21,247,000 after buying an additional 47,745 shares during the last quarter. Pzena Investment Management LLC increased its stake in USANA Health Sciences by 3.6% during the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after buying an additional 37,466 shares in the last quarter. Norges Bank purchased a new stake in USANA Health Sciences during the 4th quarter worth approximately $953,000. Finally, American Century Companies Inc. raised its holdings in shares of USANA Health Sciences by 12.3% during the fourth quarter. American Century Companies Inc. now owns 233,797 shares of the company's stock valued at $8,391,000 after acquiring an additional 25,522 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on USNA. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, Wall Street Zen raised shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday.

USANA Health Sciences Price Performance

USANA Health Sciences stock traded down $0.64 during trading on Friday, reaching $29.42. 125,464 shares of the company were exchanged, compared to its average volume of 132,920. The stock's 50 day simple moving average is $27.11 and its two-hundred day simple moving average is $32.08. The company has a market capitalization of $547.89 million, a P/E ratio of 10.40, a PEG ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a 52-week low of $23.10 and a 52-week high of $49.16.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.70 by $0.03. The company had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period in the previous year, the firm earned $0.86 earnings per share. As a group, equities analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Mulham Mulham sold 3,234 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This trade represents a 20.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,142 shares of company stock worth $655,050. Insiders own 0.63% of the company's stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.